Clinical trials: Cornea Disease
Keratoconjunctivitis Sicca
TearLab Core Validation Study to Establish Referent Values for Dry Eye Disease
This is a prospective, observational case series to determine the clinical utility of tear osmolarity and other commonly used objective tests to diagnose dry eye disease, as well as to establish referent values for objective…
- Trial name
- CVS (NCT00848198)
- Where
- 10 sites in United States, France and 3 more
- Volunteers
- 314 people, healthy volunteers welcome
- Sponsor
- TearLab Corporation
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Limbal Stem Cell Deficiency
Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency
This study will enroll subjects with qualifying limbal stem cell deficiency (LSCD). All subjects will receive CSB-001 investigational drug in either one or both study eyes.
- Trial name
- NCT06452316
- Testing
- CSB-001 Ophthalmic Solution 0.1%
- Where
- 6 sites in United States
- Volunteers
- 75 people
- Sponsor
- Claris Biotherapeutics, Inc.
Keratoconus
Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression…
- Trial name
- NCT01643226
- Testing
- riboflavin solution, KXL System
- Where
- 8 sites in United States
- Volunteers
- 230 people
- Sponsor
- Glaukos Corporation
Macular Degeneration, Diabetic Retinopathy (DR)
Artificial Intelligence-assisted Diagnosis in Ophthalmology
This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic…
- Conditions
- Macular Degeneration, Diabetic Retinopathy (DR), Glaucoma, Keratoconus
- Trial name
- AI-OPHTH-CR (NCT07497815)
- Testing
- No interventions
- Where
- 2 sites in Costa Rica
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Marisse Masis-Solano
Neurotrophic Keratitis
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
This study is to evaluate the safety and efficacy of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
- Trial name
- DEFENDO (NCT04485546)
- Testing
- cenegermin-bkbj
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dompé Farmaceutici S.p.A
Myopia, Hyperopia
Safety and Efficacy Study of Topography-Guided LASIK to Treat Myopia and Hyperopia
This purpose of this study is to evaluate the safety and effectiveness of a topography-based custom ablation treatment using the ALLEGRETTO WAVE® Eye-Q 400 Hz laser system for treating myopia and hyperopia.
- Trial name
- NCT01028378
- Testing
- T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser
- Where
- 10 sites in United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Clinical Research Consultants, Inc.
Keratitis, Corneal Ulcer
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated…
- Trial name
- NCT05255107
- Testing
- Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution
- Where
- 12 sites in United States
- Volunteers
- 468 people
- Sponsor
- Peschke GmbH
Dry Eye With Sjögren's Syndrome
A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
The purpose of this study is to investigate the superiority of KCT-0809 to placebo, and to evaluate safety in dry eye patients with Sjögren's syndrome
- Trial name
- NCT02503189
- Testing
- KCT-0809 ophthalmic solution
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Dry Eye Disease, Kerato Conjunctivitis Sicca
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Dry Eye Disease
This is a Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Signs and Symptoms of Dry Eye…
- Trial name
- NCT05119920
- Testing
- Pilocarpine Ophthalmic Topical Cream, Dose 1, Pilocarpine Ophthalmic Topical Cream, Dose 2, Pilocarpine Ophthalmic Topical Cream, Dose 3
- Where
- 19 sites in United States
- Volunteers
- 226 people
- Sponsor
- Glaukos Corporation
Dry Eye Syndromes
A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.
- Trial name
- NCT01692145
- Testing
- KCT-0809
- Where
- Japan
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes
CDL Validation Study
Ocular surface photography is significantly limited in standardization and reproducibility. This reduces its applicability for clinical monitoring of acute or chronic disease.
- Conditions
- Eyes Dry Chronic, Chronic Conjunctivitis of Both Eyes, Limbal Stem-cell Deficiency, Eye Lesion
- Trial name
- NCT05461469
- Where
- Austria
- Volunteers
- 104 people
- Sponsor
- Occyo GmbH
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive
A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)
This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
- Trial name
- NCT06563414
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Krystal Biotech, Inc.
Fuchs Endothelial Corneal Dystrophy, Fuchs
DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.
- Trial name
- NCT07024693
- Testing
- DT-168
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Design Therapeutics, Inc.
Keratoconus
Safety Study of the VEGA UV-A System to Treat Keratoconus
The purpose of this research study is to test the safety, tolerability, and effectiveness of corneal collagen cross-linking (CXL), when used to treat keratoconus.
- Trial name
- NCT01190306
- Testing
- The VEGA UV-A Illumination System, Riboflavin
- Where
- 9 sites in United States
- Volunteers
- 127 people
- Sponsor
- Topcon Medical Systems, Inc.
Keratoconus
Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus
Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.
- Trial name
- NCT07629557
- Testing
- Riboflavin Ophthalmic Solutions, UV-A Irradiation System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Glaukos Corporation
Corneal Diseases
Phase I Clinical Study of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defect
One dose group of 0.004% was used.
- Trial name
- NCT07132437
- Testing
- ZKY001 EYE DROPS
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Keratitis, Autoimmunity
A Clinical Study to Evaluate the Safety and Effectiveness of MSCohi-O Lens in the Treatment of Immune-related Ocular Surface Diseases.
Immune-related ocular surface diseases are a kind of non-infectious eye disease pedigree, which is mediated by abnormal immune system function and characterized by ocular surface tissue damage.
- Conditions
- Keratitis, Autoimmunity, Dry Eye Disease (DED)
- Trial name
- NCT07902687
- Testing
- MSCohi-O lens
- Volunteers
- 20 people
- Sponsor
- Guangdong ProCapZoom Biosciences Co., Ltd.
Keratoconjunctivitis Sicca
A Study Of Tasocitinib In Dry Eye Subjects
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease.
- Trial name
- NCT01226680
- Testing
- Tasocitinib, vehicle for Tasocitinib
- Sponsor
- Pfizer
Progressive Keratoconus
Corneal Collagen Cross-linking for Progressive Keratoconus
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
- Trial name
- CXL (NCT00647699)
- Testing
- riboflavin ophthalmic solution, UVA Irradiation
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Glaukos Corporation